Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic Stock Falls Despite Q3 Earnings and Revenue Beat, Margins Down
HOLX posts better-than-expected Q3 results, but margin contraction and regional headwinds pressure investor sentiment.
Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript
Hologic, Inc. (NASDAQ:HOLX ) Q3 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Essex D. Mitchell - Chief Operating Officer Karleen M.
Compared to Estimates, Hologic (HOLX) Q3 Earnings: A Look at Key Metrics
The headline numbers for Hologic (HOLX) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Hologic (HOLX) Q3 Earnings and Revenues Beat Estimates
Hologic (HOLX) came out with quarterly earnings of $1.08 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.06 per share a year ago.
Hologic Focuses on Breast Health Turnaround This Year: Can It Deliver?
HOLX eyes a Breast Health rebound in Q4, backed by leadership changes, new strategy and Endomag momentum.
Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
HOLX vs. EXAS: Which Cancer Diagnostics Stock Should You Retain Now?
EXAS gains edge over HOLX as rising Cologuard adoption, new launches and bullish EPS trends boost investor appeal.
Hologic's International Momentum Takes Shape: Will Execution Pay Off?
HOLX is leaning into international growth with Surgical division strength and untapped demand driving momentum abroad.
Hologic (HOLX) Laps the Stock Market: Here's Why
In the closing of the recent trading day, Hologic (HOLX) stood at $65.37, denoting a +2.64% move from the preceding trading day.
Hologic Q3 Preview: Tariff Pressure And Undervalued Stock Price, Initiate With Buy
I am initiating a Buy rating on Hologic, Inc. with a fair value of $81, as current risks are priced in. Hologic's strong diagnostic portfolio, recurring consumables revenue, and expanding assay menu support long-term growth in women's health. Short-term margin pressure from tariffs is expected, but normalization and margin expansion should resume from FY26 onward.
Is Hologic Stock a Risky Investment Ahead of Its Q3 Earnings Report?
HOLX heads into Q3 earnings with revenue and EPS estimates down, tariff pressures mounting, and stock lagging peers.
